Biohaven Pharmaceutical Holding Company Ltd.
Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers

Abstract:

Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions including the immunotherapeutic agents and glutamate modulating agents are also disclosed.